Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hyaluronidase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    51 result(s) found for: Hyaluronidase. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2019-001151-40 Sponsor Protocol Number: CTU148N Start Date*: 2019-07-09
    Sponsor Name:RIEMSER Pharma GmbH
    Full Title: Phase II pilot study: To determine an effective and tolerable dose of Hylase® "Dessau" (bovine hyaluronidase) in the treatment of hyaluronic acid filler overshoots by injection into defined areas o...
    Medical condition: In this study, healthy subjects get an artificial over-injection with Hyaluron acid filler on the back of the hands. To demonstrate the effectiveness of hylase® "Dessau" as an antidote for hyaluro...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001203-19 Sponsor Protocol Number: AN 05/6922 Start Date*: 2005-09-19
    Sponsor Name:Department of research & development, TheLeeds teaching hospitals NHS trust
    Full Title: Does Hyaluronidase permit volume reduction in sub-Tenon anaestehesia?
    Medical condition: Cataract
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004068-13 Sponsor Protocol Number: HALO-109-301 Start Date*: 2016-03-02
    Sponsor Name:Halozyme, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab-Paclitaxel Plus Gemcitabine Compared With P...
    Medical condition: Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) HU (Completed) BE (Completed) GB (Prematurely Ended) LT (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) FR (Completed) HR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000206-38 Sponsor Protocol Number: 54767414MMY3012 Start Date*: 2017-10-04
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) GR (Completed) ES (Ongoing) FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003453-18 Sponsor Protocol Number: RH-2015-200 Start Date*: 2015-11-25
    Sponsor Name:Rigshospitalet
    Full Title: A Randomized, Single-blinded, Cross-over Study investigating the Non-inferiority of Efficacy and Safety of HyQvia in comparison with Conventional Subcutaneous Ig Therapy in Multifocal Motor Neuropa...
    Medical condition: Multifocal Motor Neuropathy (MMN)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10064135 Polyneuropathy chronic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-005496-87 Sponsor Protocol Number: 161403 Start Date*: 2015-10-15
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human...
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DK (Completed) DE (Completed) SE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) NO (Completed) SK (Completed) GR (Completed) AT (Completed) PL (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024099-25 Sponsor Protocol Number: MO22982 Start Date*: 2011-09-21
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, multi-center cross-over study to evaluate patient preference and Health Care Professional (HCP) satisfaction with subcutaneous (SC) administration of trastuzumab in HER2-positive earl...
    Medical condition: Cáncer de mama precoz HER2 positivo
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) SE (Completed) GB (Completed) DK (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001618-27 Sponsor Protocol Number: EMN14/54767414MMY3013 Start Date*: 2017-05-19
    Sponsor Name:European Myeloma Network (EMN)
    Full Title: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy Wi...
    Medical condition: Relapsed or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing) ES (Ongoing) BE (Ongoing) DE (Ongoing) CZ (Ongoing) DK (Completed) FR (Ongoing) NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004333-33 Sponsor Protocol Number: EMN22/54767414AMY2005 Start Date*: 2019-07-08
    Sponsor Name:European Myeloma Network
    Full Title: Phase 2 study of daratumumab monotherapy in previously untreated patients with stage 3B light chain (AL) amyloidosis
    Medical condition: Patients with newly diagnosed stage 3B AL amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10002022 Amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing) NL (Ongoing) FR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003715-28 Sponsor Protocol Number: HALO-109-201 Start Date*: 2011-12-08
    Sponsor Name:Halozyme, Inc.
    Full Title: A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine Combined with PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Compared to Gemcitabine...
    Medical condition: Metastatic Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000481-38 Sponsor Protocol Number: 161102 Start Date*: 2012-06-28
    Sponsor Name:Baxter Innovations GmbH
    Full Title: Tolerability, Safety and Product Administration Evaluation of rHuPH20 Facilitated Subcutaneous Treatment with Immune Globulin (Human), 10% in Subjects with Primary Immunodeficiency Diseases – A Stu...
    Medical condition: Primary Immunodeficiency Diseases
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10036700 Primary immunodeficiency syndromes HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000525-25 Sponsor Protocol Number: 61186372NSC3004 Start Date*: 2022-09-05
    Sponsor Name:JANSSEN CILAG INTERNATIONAL NV
    Full Title: A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous on Body Deliv...
    Medical condition: EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) PL (Ongoing) ES (Ongoing) PT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002282-19 Sponsor Protocol Number: ΕΑΕ-2018/ΜΜ03 Start Date*: 2018-09-28
    Sponsor Name:Hellenic Society of Hematology
    Full Title: A Phase 2, Multicenter, Open-label, Single-Arm Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Ixazomib and Dexamethasone as Second Line Therapy in Multiple Myeloma Pat...
    Medical condition: Relapsed and /or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004203-41 Sponsor Protocol Number: 54767414MMY2040 Start Date*: 2018-04-26
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-000828-28 Sponsor Protocol Number: 52642 Start Date*: 2016-07-26
    Sponsor Name:UMC Utrecht
    Full Title: Titlle: Subcutaneous immunoglobulins with rHuPH20 in multifocal motor neuropathy (MMN) It is an interventional cross-over study where the use of the combination of subcutaneous immunoglobulins ...
    Medical condition: Non-inferiority and safety/tolerance of Hyqvia compared to IVIg in 20 MMN patients with at least one conduction block on EMG and stable on IVIg.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001540-22 Sponsor Protocol Number: MD2019 Start Date*: 2020-01-22
    Sponsor Name:Abteilung für Hals- Nasen- Ohrenkrankheiten MUW, AKH Wien
    Full Title: Assessment of vertigo control rate following common treatments in Menière´s disease
    Medical condition: In our study we try to evaluate the the effect of common therapies in Menière´s disease patients on vertigo control calculation, Hydrops MRI, vHIT (video head impuls test) , caloric testing, audiol...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004603-31 Sponsor Protocol Number: PH1603 Start Date*: 2017-12-04
    Sponsor Name:PH Research
    Full Title: A pilot trial of PEGPH20 (pegylatedhyaluronidase) in combination with avelumab (anti-PD-L1 MSB0010718C) in chemotherapy resistant pancreatic cancer
    Medical condition: chemotherapy resistant advanced or locally advanced pancreatic ductal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000083-24 Sponsor Protocol Number: 0624-206 Start Date*: 2012-05-14
    Sponsor Name:ViroPharma Incorporated
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, DOSERANGING, CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF CINRYZE® (C1 ESTERASE INHIBITOR [HUMAN]) WITH RE...
    Medical condition: Angioedema.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10019860 Hereditary angioedema PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) ES (Completed) DE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002918-41 Sponsor Protocol Number: IJB-EBC-Decrescendo-2020 Start Date*: 2021-08-25
    Sponsor Name:Institut Jules Bordet
    Full Title: De-Escalation of neoadjuvant ChemotheRapy in HER2-positive, EStrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chem...
    Medical condition: HER2-positive, estrogen receptor (ER)-negative/progesterone receptor (PR)-negative, node-negative early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) IT (Prematurely Ended) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001545-13 Sponsor Protocol Number: 54767414MMY3019 Start Date*: 2019-01-23
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma ...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) CZ (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:40:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA